Log In Sign up
The largest database of trusted experimental protocols

Dako her2 cish pharmdx kit

Manufactured by Agilent Technologies
Visit Supplier
Sourced in Denmark

The Dako Her2 CISH pharmDx Kit is a chromogenic in situ hybridization (CISH) assay designed to detect HER2 gene amplification in formalin-fixed, paraffin-embedded breast cancer tissue specimens. The kit provides reagents and materials necessary to perform the test.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

HER2 CISH pharmDx kit PharmDx kit Dako kits

2 protocols using dako her2 cish pharmdx kit

1

HER2 CISH Amplification Assessment

Check if the same lab product or an alternative is used in the 5 most similar protocols
CISH was performed according to the manufacturer’s protocol (Dako Her2 CISH pharmDx Kit; Dako, Glostrup, Denmark). Areas with the highest HER2 counts with non-overlapping nuclei were analysed by counting HER2 and centromeric probe 17 (CEP17) signals in at least 40 nuclei. The ratio HER2/CEP17 was calculated. A case was considered HER2 amplified when the signal ratio was ≥2.0 or when HER2 signal cluster was observed.
Coati I., Lotz G., Fanelli G.N., Brignola S., Lanza C., Cappellesso R., Pellino A., Pucciarelli S., Spolverato G., Guzzardo V., Munari G., Zaninotto G., Scarpa M., Mastracci L., Farinati F., Realdon S., Pilati P., Lonardi S., Valeri N., Rugge M., Kiss A., Loupakis F, & Fassan M. (2019). Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. British Journal of Cancer, 121(3), 257-263.
+ Open protocol
+ Expand
2

HER2 Amplification Assessment by CISH

Check if the same lab product or an alternative is used in the 5 most similar protocols
CISH was performed according to the manufacturer’s protocol (Dako Her2 CISH pharmDx Kit; Dako, Glostrup, Denmark). Areas with the highest HER2 counts with non-overlapping nuclei were analyzed by counting HER2 and centromeric probe 17 (CEP17) signals in at least 40 nuclei. The ratio HER2/CEP17 was calculated. A case was considered HER2 amplified when the signal ratio was ≥2.0 or when HER2 signal cluster was observed.
Pellino A., Brignola S., Riello E., Niero M., Murgioni S., Guido M., Nappo F., Businello G., Sbaraglia M., Bergamo F., Spolverato G., Pucciarelli S., Merigliano S., Pilati P., Cavallin F., Realdon S., Farinati F., Dei Tos A.P., Zagonel V., Lonardi S., Loupakis F, & Fassan M. (2021). Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. Journal of Personalized Medicine, 11(11), 1095.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!